Cogstate Ltd · ASX:CGS

Cogstate — Investor Presentation (June 2015)

22 slides from Cogstate's investor presentation, June 2015

  1. Slide 1: Investor Presentation Business Update June 2015

    INVESTOR PRESENTATION BUSINESS UPDATE JUNE 2015

  2. Slide 2: Cogstate

    COGSTATE • Founded in 1999 • Listed on Australian Securities Exchange in 2004 (ASX.CGS) • >90 employees across 4 global locations AUSTRALIA UNITED STATES UNITED STATES SPAIN Melbourne New Haven, CT New York, NY Barcelona © 2015 Cogstate Ltd. All rights reserved. 2

  3. Slide 3: Leaders in the Measurement of Cognition

    LEADERS IN THE MEASUREMENT OF COGNITION 1 COGNITION = THINKING Attention | Memory | Learning | Reasoning | Comprehension COGNITIVE CHANGE IS 2 IMPORTANT TO MEASURE Neurological Disease | Head injury | Drug Effect © 2015 Cogstate Ltd. All rights reserved. 3

  4. Slide 4: © 2015 Cogstate Ltd. All rights reserved.

    © 2015 Cogstate Ltd. All rights reserved. 4

  5. Slide 5: Cogstate Solutions Portfolio

    COGSTATE SOLUTIONS PORTFOLIO © 2015 Cogstate Ltd. All rights reserved. 5

  6. Slide 6: Cogstate Clinical Trials – Driving Revenue Growth & Profitability

    COGSTATE CLINICAL TRIALS – DRIVING REVENUE GROWTH & PROFITABILITY © 2015 Cogstate Ltd. All rights reserved. 6

  7. Slide 7: Full Service Solution for Measuring Cognition in Clinical Trials

    FULL SERVICE SOLUTION FOR MEASURING COGNITION IN CLINICAL TRIALS © 2015 Cogstate Ltd. All rights reserved. 7

  8. Slide 8: Accurate and Universal Testing Solution

    ACCURATE AND UNIVERSAL TESTING SOLUTION © 2015 Cogstate Ltd. All rights reserved. 8

  9. Slide 9: Cogstate: Summary of Phase III Studies and Disease Areas

    COGSTATE: SUMMARY OF PHASE III STUDIES AND DISEASE AREAS Phase IV (4) • 30 Phase III industry-sponsored studies Phase III (30) • Disease areas include: Phase I Alzheimer’s disease Parkinson's Disease (103) Major Depressive Disorder Schizophrenia Oncology Bipolar Depression Phase II (81) Anemia Overa

  10. Slide 10: Key Financial Features of Clinical Trials Business

    KEY FINANCIAL FEATURES OF CLINICAL TRIALS BUSINESS • Clinical Trials is our key revenue driver– accounting for 97% of proforma sales in FY14. • Our revenue is driven by the volume of clinical trials, not their success. This differentiates Cogstate to many other companies in this space. • Contract li

  11. Slide 11: Momentum in Our Clinical Trials Business Is Building

    MOMENTUM IN OUR CLINICAL TRIALS BUSINESS IS BUILDING • We are seeing renewed sales momentum in Clinical Trials, with a significant increase in new contracts signed in FY15 year to date. • As a result, our contracted revenue pipeline for FY16 is significantly ahead of where we started FY15. • Our sal

  12. Slide 12: Momentum in Our Clinical Trials Business Is Building

    MOMENTUM IN OUR CLINICAL TRIALS BUSINESS IS BUILDING • We are seeing renewed sales momentum in Clinical Trials, with a significant increase in new contracts signed in FY15 year to date. • As a result, our contracted revenue pipeline for FY16 is significantly ahead of where we started FY15. • Our sal

  13. Slide 13: Momentum in Our Clinical Trials Business Is Building

    MOMENTUM IN OUR CLINICAL TRIALS BUSINESS IS BUILDING • We are seeing renewed sales momentum in Clinical Trials, with a significant increase in new contracts signed in FY15 year to date. • As a result, our contracted revenue pipeline for FY16 is significantly ahead of where we started FY15. • Our sal

  14. Slide 14: What Is Driving This Momentum?

    WHAT IS DRIVING THIS MOMENTUM? FULLY • Targeted strategy delivering results RESOURCED • Utilisation of Subject Matter Experts COMMERCIAL (SMEs) SALES TEAM • Identification and execution of RFPs • Alzheimers/Dementia FAVOURABLE Increased trial activity looking at early stage disease / prevention INDU

  15. Slide 15: Cogstate Precision Recruitment for Clinical Trials – A New Revenue Stream

    COGSTATE PRECISION RECRUITMENT FOR CLINICAL TRIALS – A NEW REVENUE STREAM © 2015 Cogstate Ltd. All rights reserved. 15

  16. Slide 16: Momentum to Be Augmented by New Revenue Stream – Precision Recruitment

    MOMENTUM TO BE AUGMENTED BY NEW REVENUE STREAM – COGSTATE PRECISION RECRUITMENT NEW REVENUE STREAMS SCIENCE INNOVATION © 2015 Cogstate Ltd. All rights reserved. 16

  17. Slide 17: Momentum to Be Augmented by New Revenue Stream – Precision Recruitment

    MOMENTUM TO BE AUGMENTED BY NEW REVENUE STREAM – COGSTATE PRECISION RECRUITMENT AN INNOVATIVE ONLINE SCREENING TOOL DESIGNED TO DELIVER A POOL OF PREQUALIFIED PARTICIPANTS TO CLINICAL TRIAL SITES Less on-site failure = lower cost and reduced recruitment timelines • Current screen-fail rate at site,

  18. Slide 18: Cogstate Recruitment Process

    COGSTATE RECRUITMENT PROCESS 1a COGNITION REGISTRY is analysed to identify potential participants STUDY COGNITION 1b Study advertising invites general ADVERTISING REGISTRY Study advertising invites general participation participation. 2 PRECISION PRECISION RECRUITMENT allall pre-screens participants

  19. Slide 19: Cogstate Board & Investment Summary

    COGSTATE BOARD & INVESTMENT SUMMARY © 2015 Cogstate Ltd. All rights reserved. 19

  20. Slide 20: A High Calibre International Board

    A HIGH CALIBRE INTERNATIONAL BOARD • BRAD O’CONNOR - CEO • MARTYN MYER AO - Chairman Founder with long history of supporting neurosciences in Aust. • DAVID DOLBY - Non-Executive Director Director Dolby Laboratories Inc. and Dolby Family Ventures, an early stage venture firm focused on building great

  21. Slide 21: Summary: Investment Highlights

    SUMMARY: INVESTMENT HIGHLIGHTS • A leader in the measurement of cognition – providing services and software across four key areas. • Clinical trials is our main revenue driver (97% of FY14 proforma sales). Importantly, we are reliant on the volume of clinical trials, not their success. This is a key

  22. Slide 22: Cogstate

    COGSTATEG ASSESS + MONITOR « IMPROVE

Cogstate — Investor Presentation (June 2015) on 6ix